scholarly journals SP1.1.2Perineal reconstruction following extralevator abdominoperineal excision of rectum - Is IGAP flap a feasible option

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Prem Thambi ◽  
Wafa Abdul Muiz Dzihni ◽  
Trisha Jha ◽  
Haroon Siddiqui ◽  
Madan Jha

Abstract Aim Extra-levator abdomino-perineal excision for low rectal cancer has been shown to reduce tumor perfoation rates and incidence of local recurrence when compared to a conventional abdominoperineal excision. This is however associated with increased wound complications. This study was done to evaluate the feasibility of an inferior gluteal artery flap in patients undergoing ELAPE. Methods This was retrospective analysis was done at tertiary centre for all patients who underwent an ELAPE over a period of 7 years (December 2013 to July 2020). Patient demographic, relevant co morbidities and the data regarding chemotherapy and radiotherapy were analysed. Results A Total of 33 patients underwent ELAPE with an IGAP flap wound reconstruction. The mean age was 68 (44-86) with a mean BMI of 27 (25-45). 26 patients out of 33 (82%) received neoadjuvant treatment for cancer. The mean LoS was 11 days (6-31). The perineal wound complications were graded as per Clavein Dindo classification and 56 % had no wound complications recorded. 07/33 had Grade I and 06/33 had Grade II complications. Conclusion IGAP flap closure for perineal defects, does offer the advantage of compatibility with both minimally invasive and open procedures and the avoidance of using irradiated tissue. This case series does demonstrate the feasibility of IGAP flaps as viable option to cover perineal defects following radical low rectal cancer surgery with low morbidity.

2019 ◽  
Vol 62 (12) ◽  
pp. 1477-1484 ◽  
Author(s):  
Jia Gang Han ◽  
Zhen Jun Wang ◽  
Zhi Gang Gao ◽  
Guang Hui Wei ◽  
Yong Yang ◽  
...  

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
E Lau ◽  
Z Arshad ◽  
A Aslam ◽  
A Thahir ◽  
M Krkovic

Abstract Introduction Osteomyelitis refers to an inflammatory process affecting bone and bone marrow. This study reviews chronic femoral osteomyelitis treatment and outcomes, including economic impact. Method We retrospectively collected data from a consecutive series of 14 chronic femoral osteomyelitis patients treated between January 2013 and January 2020. Data collected include patient demographics, comorbidities, pathogens, complications, treatment protocol and costs. Functional outcome was assessed using EuroQOL five-dimensional interview administration questionnaire (EQ-5D-5L™) and EuroQOL Visual Analogue Scale (EQ-VAS™). Results Of these, 92.9% had one or more osteomyelitis risk factor, including smoking and diabetes. Samples from 78.6% grew at least one pathogen. Only 42.9% achieved remission after initial treatment, but 85.7% were in remission at final follow-up, with no signs of recurrence throughout the follow-up period (mean: 21.4 months). The average treatment cost was £39,249.50 with a net mean loss of £19,080.10 when funding was considered. The mean-derived EQ-5D score was 0.360 and the mean EQ-VAS score was 61.7, lower than their values for United Kingdom’s general population, p = 0.0018 and p = 0.013 respectively. Conclusions Chronic femoral osteomyelitis treatment is difficult, resulting in significant economic burden. With previous studies showing cheaper osteomyelitis treatment at specialist centres, our net financial loss incurred suggests the need for management at specialised centres.


Gut ◽  
2015 ◽  
Vol 64 (Suppl 1) ◽  
pp. A387.2-A388
Author(s):  
J Blong ◽  
A Chhabra ◽  
K James ◽  
P Arumagam ◽  
M Feldman

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Qingbin Wu ◽  
Zechuan Jin ◽  
Xubing Zhang ◽  
Xiangbing Deng ◽  
Yong Peng ◽  
...  

2018 ◽  
Vol 131 (11) ◽  
pp. 1268-1274 ◽  
Author(s):  
Yi Zheng ◽  
Jia-Gang Han ◽  
Zhen-Jun Wang ◽  
Zhi-Gang Gao ◽  
Guang-Hui Wei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document